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The homeostatic balance of hepatic glucose utiliza-
tion, storage, and production is exquisitely con-
trolled by hormonal signals and hepatic carbon
metabolism during fed and fasted states. How the
liver senses extracellular glucose to cue glucose
utilization versus production is not fully understood.
We show that the physiologic balance of hepatic
glycolysis and gluconeogenesis is regulated by Bcl-
2-associated agonist of cell death (BAD), a protein
with roles in apoptosis and metabolism. BAD defi-
ciency reprograms hepatic substrate and energy
metabolism toward diminished glycolysis, excess
fatty acid oxidation, and exaggerated glucose pro-
duction that escapes suppression by insulin. Genetic
and biochemical evidence suggests that BAD’s
suppression of gluconeogenesis is actuated by
phosphorylation of its BCL-2 homology (BH)-3
domain and subsequent activation of glucokinase.
The physiologic relevance of these findings is
evident from the ability of a BAD phosphomimic
variant to counteract unrestrained gluconeogenesis
and improve glycemia in leptin-resistant and high-
fat diet models of diabetes and insulin resistance.
INTRODUCTION
Hepatic glucose production (HGP) is central to metabolic adap-
tation during fasting, and its abnormal elevation is a chief deter-
minant of fasting hyperglycemia in diabetes (Lin and Accili, 2011;
Rizza, 2010). During short-term fasting, glucose is produced by
both net glycogenolysis and gluconeogenesis (Rothman et al.,
1991), whereas upon prolonged fasting, glucose is synthesized
almost exclusively from gluconeogenesis. Gluconeogenesis
and glycolysis are competing pathways that are reciprocally272 Cell Metabolism 19, 272–284, February 4, 2014 ª2014 Elsevier Inregulated by glucagon and insulin during fasted and fed states,
respectively. In addition to transcriptional regulation, changes
in hepatic carbon flux can exert allosteric effects on gluconeo-
genic enzymes (Magnuson et al., 2003). Hepatic substrate flux
is further intertwined with fatty acid oxidation (FAO), tricarboxylic
acid (TCA) cycle, and mitochondrial electron transport chain
activity, which supply the gluconeogenic pathway with carbon
substrates, reducing equivalents, and ATP (Satapati et al., 2012).
We have previously shown that the BCL-2 family protein Bcl-
2-associated agonist of cell death (BAD) has an alternative func-
tion in glucose metabolism, separate from its role in apoptosis
(Danial, 2008; Danial et al., 2003; Danial et al., 2008). BAD’s
metabolic effect is dependent on its ability to activate glucoki-
nase (GK) and modulate glucose oxidation (Danial, 2008; Danial
et al., 2008). GK is the product of the maturity-onset diabetes of
the young type 2 (MODY2) gene that exerts tissue-restricted
functions (Matschinsky, 2009). In liver, GK regulates substrate
utilization and storage by stimulating glycogen and lipid synthe-
sis while suppressing hepatic glucose production (Postic et al.,
1999; Rossetti et al., 1997; Velho et al., 1996). In b cells, GK is
critical for glucose regulation of insulin secretion (Matschinsky,
2009). We previously reported that in b cells, GK activation and
glucose sensing are attuned to BAD phosphorylation on S155
within an amphipathic a-helical region known as the BCL-2
homology (BH)-3 domain. BAD S155 is the target of multiple
kinases that either phosphorylate S155 directly or modify
upstream priming phosphorylation sites, facilitating S155 phos-
phorylation (reviewed in Danial, 2008). Phosphorylation of the
BH3 domain not only triggers BAD’s metabolic function, but
also suppresses its apoptotic activity. Importantly, the phos-
pho-BAD BH3 helix is both required and sufficient for BAD’s
metabolic function (Danial et al., 2008). Recent biochemical
and structural dissection of the BAD-GK complex has revealed
that the phospho-BAD BH3 helix directly engages GK near its
active site and increases the Vmax of the enzyme without drastic
effects on its glucose affinity (Szlyk et al., 2014).
Beyond b cell abnormalities, the contribution of altered
hepatic metabolism to glucose homeostasis defects associated
with loss of BAD has not been examined. This is especiallyc.
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liver are distinct from b cells (Matschinsky, 2009). Here, we use a
combination of informative genetic models and BAD mutants to
investigate the significance of BAD and its partnership with GK in
hepatic substrate utilization and glucose production. Moreover,
we probe the physiologic relevance of hepatic BAD in restoring
proper control of glucose production in the leptin-resistant and
high-fat diet models of diabetes and insulin resistance.
RESULTS
BAD-Dependent Modulation of Hepatic Glucose
Metabolism
To define the contribution of altered hepatic metabolism to
glucose homeostasis abnormalities in Bad/ mice, we initially
focused on glycolytic and gluconeogenic pathways. In primary
Bad/ hepatocytes, lactate production in response to glucose
was diminished (Figure 1A), and gluconeogenesis was signi-
ficantly exaggerated, as apparent from glucose release in
response to lactate and pyruvate (Figure 1B). These observa-
tions suggest that the net balance of glycolysis and gluconeo-
genesis is shifted toward gluconeogenesis in the absence of
BAD. Pyruvate tolerance tests (PTTs) confirmed that Bad/
mice display significantly higher gluconeogenic conversion of
pyruvate to glucose in vivo (Figure 1C). Importantly, knockdown
of Bad in primary wild-type hepatocytes was sufficient to reduce
glycolysis and enhance gluconeogenesis (Figures 1D and 1E),
indicating an acute and cell-autonomous role for BAD in these
processes.
Impaired PTT in Bad/ mice is consistent with changes in
hepatic glucose metabolism. However, secondary changes
due to chronic whole-body deletion of Bad cannot be excluded.
To directly examine the relevance of hepatic BAD in vivo, Bad
was knocked down in the liver of C57BL/6J mice following tail
vein delivery of adenoviruses bearing Bad shRNA or control
(scrambled) sequence (Figure S1A available online). Hepatic
depletion of BAD manifested in excess glucose production dur-
ing PTT and fasting hyperglycemia (Figure 1F). In addition, acute
hepatic knockdown of Bad resulted in impaired glucose toler-
ance (Figure S1B), similar to Bad/ mice (Danial et al., 2003).
Notably, hepatic depletion of BAD did not alter insulin secretion
in response to a glucose challenge in vivo (Figure S1C). In addi-
tion, fed and fasted insulin levels were comparable in mice
treated with Bad shRNA versus control shRNA (Figure S1D).
Collectively, the above in vitro and in vivo observations indicate
that hepatic BAD influences the fate of pyruvate and is relevant
for the proper regulation of glucose utilization and production
in the liver.
Hepatic pyruvate metabolism is regulated, at least in part, at
the transcriptional level downstream of hormonal and nutrient
signaling (Lin and Accili, 2011). Initial examination of gluconeo-
genic and glycolytic genes in fed and fasted Bad/ and Bad
knockdown liver indicated changes in several genes. In partic-
ular, mRNA levels of the gluconeogenic enzyme phosphoenol-
pyruvate carboxykinase (Pck) 1 were significantly elevated, while
mRNA levels of the glycolytic enzyme liver-type pyruvate kinase
(L-Pk) were significantly diminished (Figures 1G, 1H, and
S1E). Other gluconeogenic genes (fructose 1,6-bisphosphatase
[Fbp] 1 and glucose 6-phosphatase [G6Pase]) were alsoCell Mincreased in Bad/ liver (Figure S1E). This is further consistent
with BAD-dependent reciprocal changes in hepatic glycolysis
and gluconeogenesis.
In addition to transcriptional control during fed and fasted
states, L-Pk and Pck1 expression can be regulated by glucose.
Specifically, the promoters of both genes are glucose sensitive
in that increased glucose metabolism through GK stimulates
L-Pk transcription and represses that of Pck1 (Cournarie et al.,
1999; Scott et al., 1998; Yamada and Noguchi, 1999). Based
on these reports, we predicted that glucose modulation of
L-Pk and Pck1 transcription may be altered upon hepatic deple-
tion of BAD and the attendant diminution of glucosemetabolism.
This was indeed the case. In wild-type hepatocytes, L-PkmRNA
levels were elevated at high, compared to low, glucose concen-
trations (25 mM versus 5 mM), whereas Pck1 mRNA levels
showed the opposite profile (Figures S1F and S1G). Bad knock-
down, however, resulted in higher Pck1 mRNA levels that were
especially exaggerated at low glucose (Figure S1F). In com-
parison, glucose stimulation of L-Pk transcripts was significantly
reduced (Figure S1G).
The above observations in both cultured hepatocytes and
whole animals using a combination of biochemical and tran-
scriptional readouts suggest that BAD is required for proper
interpretation of glucose signals. Notably, the metabolic
outcome of BAD depletion in the liver was phenocopied in
mice treated with Gk shRNA (Figure S1H). This is evident from
exaggerated glucose levels during PTT, significant elevation of
hepatic Pck1 mRNA levels, and diminution of L-Pk transcripts,
as well as impaired glucose tolerance (Figures 1I–1K and S1I).
Given the biochemical interaction between BAD and GK (Danial
et al., 2003, 2008; Szlyk et al., 2014), these sharedmetabolic out-
comes suggest that their functional partnership may be relevant
for the proper control of glycolysis and gluconeogenesis in the
liver (see below).
We have previously reported that BAD’s capacity to activate
GK in b cells is triggered by S155 phosphorylation (aa enumera-
tion based on the mouse sequence of BAD) (Danial et al., 2008).
Importantly, S155 phosphorylation is sensitive to nutrient status
in both b cells (Danial et al., 2008) and liver (Figure 2A). Specif-
ically, BAD S155 phosphorylation is induced upon refeeding. In
addition, the phosphorylation of two priming serine residues up-
stream of the BAD BH3 domain, S112 and S136, is similarly
increased upon refeeding (Figure 2A). These observations
suggest that BAD phosphorylation and metabolic activity may
be integrated with nutritional states. Consistent with this
idea, interference with BAD phosphorylation through a Bad
S155A nonphosphorylatable knockin allele was associated
with fasting hyperglycemia and excess glucose release during
PTT (Figure 2B).
To interrogate the direct significance of BAD phosphorylation
specifically in the liver, we carried out whole animal liver recon-
stitution assays in Bad/ mice using adenoviruses expressing
wild-type or defined phosphorylation mutants within the BAD
BH3 domain. Hepatic reconstitution with wild-type BAD lowered
the glucose values during PTT, indicating that exaggerated
gluconeogenesis in Bad/ is directly related to the loss of
BAD function in the liver (Figure 2C). Given BAD’s dual capacity
to engage GK and influence glucose metabolism on one hand,
and to bind select BCL-2 protein (BCL-2, BCL-XL, and BCL-w)etabolism 19, 272–284, February 4, 2014 ª2014 Elsevier Inc. 273
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Figure 1. Hepatic Glucose Metabolism in the Absence of BAD
(A) Glucose-stimulated lactate production by primary Bad+/+ and Bad/ hepatocytes (n = 5–8).
(B) Glucose release by Bad+/+ and Bad/ hepatocytes treated with lactate and pyruvate (n = 6).
(legend continued on next page)
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Figure 2. The Effect of BAD Phosphoryla-
tion on Gluconeogenesis
(A) Immunoblot analysis and quantification of
relative BAD phosphorylation on S155, S136, and
S112 in liver samples derived from C57BL/6J mice
fasted overnight and refed for 6 hr after overnight
fasting.
(B) PTT in Bad+/+ and S155A knockin mice
(n = 10–11).
(C) PTT in Bad+/+ and Bad/ mice following
hepatic reconstitution with the indicated adenovi-
ruses (n = 16–24). Asterisks compare Bad/:BAD
S155D versus Bad/:GFP; # indicates a com-
parison of Bad/:BAD WT versus Bad/:GFP.
(D) Glucose production in primary Bad/ hepa-
tocytes reconstituted with the indicated adenovi-
ruses and treated with lactate and pyruvate (n =
7–12). Error bars show ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001; n.s., nonsignificant. See also
Figure S2.
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definitive role for BAD’smetabolic function in regulation of gluco-
neogenesis could not be inferred solely based on the phenotype
of wild-type BAD in these assays. Therefore, we examined three
separate BAD phosphorylation mutants that are competent or
deficient in activating GK (Figure S2A). The phosphomimic
S155D mutation triggers BAD’s capacity to activate GK while
blocking its interaction with BCL-2 protein partners (Danial(C) PTT in Bad+/+ and Bad/ mice (n = 14–20).
(D) Lactate production in Bad knockdown hepatocytes 8 hr after glucose stimulation (n = 9).
(E) Glucose production in Bad knockdown hepatocytes treated with lactate and pyruvate (n = 3–5).
(F) PTT in C57BL/6J mice after hepatic knockdown of Bad (n = 12–17).
(G and H) Relative hepatic mRNA levels of Pck1 (G) and L-Pk (H) in fed and overnight-fasted C57BL/6J mice
(I) PTT in C57BL/6J mice after hepatic knockdown of Gk (n = 8–12).
(J and K) Relative hepatic mRNA levels of Pck1 (J) and L-Pk (K) in fed and overnight-fasted C57BL/6J mice
show ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1.
Cell Metabolism 19, 272–284et al., 2008). Hepatic reconstitution with
this mutant was sufficient to restore GK
activity and correct the PTT profile of
Bad/ mice (Figures 2C and S2B).
The corresponding phospho-deficient
variant, BAD S155A, which is compro-
mised in its capacity to restore hepatic
GK activity in Bad/ mice (Figure S2B),
did not correct the glucose values during
PTT (Figure 2C). Although diminished in
its ability to activate GK, BAD S155A re-
tains its capacity to interact with BCL-2
family partners (Danial, 2008) and is
therefore not a direct control for S155D
GK-activating variant, which does not
bind to BCL-2 family proteins (Fig-
ure S2A). For these reasons, we used a
second phospho-deficient BAD variant
that has diminished GK-activating capac-
ity but cannot bind BCL-2 family partners
(BAD L151A, S155A, and D156A triplemutant referred to as BAD AAA) (Figures S2A and S2B) (Danial
et al., 2008). Parallel comparison of this mutant with BAD
S155D allowed assessment of BAD’s capacity to engage and
activate GK separate from its ability to bind BCL-2 family part-
ners. Unlike BAD S155D, BAD AAA did not restore the PTT
profile in Bad/ mice (Figure 2C). Furthermore, in vitro genetic
reconstitution studies using these variants were consistent
with the above observations in that BAD S155D, but not BADafter hepatic knockdown of Bad (n = 10).
after hepatic knockdown of Gk (n = 5). Error bars
, February 4, 2014 ª2014 Elsevier Inc. 275
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Figure 3. BAD-Dependent Modulation of Hepatic Energy Metabolism
(A) Mitochondrial OCR in primary Bad+/+ and Bad/ hepatocytes transduced with the indicated adenoviruses and treated with lactate and pyruvate (n = 4).
(B) Mitochondrial OCR in primary Bad+/+ and Bad/ hepatocytes treated with palmitate (n = 10).
(C) Etomoxir (Etx) inhibition of OCR in primary hepatocytes treated with lactate and pyruvate (n = 5).
(D) Respiratory quotient in Bad+/+ and Bad/ mice (n = 8).
(E and F) Comparison of mitochondrial mass as examined by the protein levels of Voltage-dependent anion channel (VDAC) using western blot analysis (E) and by
the fluorescence signal intensity of MitoTracker Green in Bad+/+ and Bad/ primary hepatocytes (F) (n = 3). Scale bar in (F), 10 mm. Error bars show ± SEM. **p <
0.01; ***p < 0.001; n.s., nonsignificant. See also Figure S3 and Table S1.
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Regulation of Fasting Response by Hepatic BADS155A or BAD AAA, corrected gluconeogenesis in Bad/ hepa-
tocytes to levels comparable to those of GFP-expressing Bad+/+
controls (Figure 2D). Thus, in vivo and in vitro interference with
BAD S155 phosphorylation is associated with unrestrained
gluconeogenesis and phenocopies the changes in hepaticmeta-
bolism observed in Bad/ and Bad knockdown liver.
BAD’s Effect on Mitochondrial Energy Metabolism in
Hepatocytes
Mitochondria play a pivotal role in gluconeogenesis through pro-
vision of carbon substrates, reducing equivalents, and ATP
(Burgess et al., 2007; Satapati et al., 2012). Metabolic flux anal-
ysis has also uncovered a tight connection between PCK1, mito-
chondrial bioenergetics, and TCA cycle (Burgess et al., 2007;
Hakimi et al., 2005; Satapati et al., 2012). To assess how Bad/276 Cell Metabolism 19, 272–284, February 4, 2014 ª2014 Elsevier Inhepatocytes derive the ATP required to support excess gluco-
neogenesis, we focused on mitochondrial energy metabolism.
We reasoned that gluconeogenesis from exogenous lactate
and pyruvate would create a state of energy demand, driving
ATP production by mitochondrial oxidative phosphorylation,
which can be deduced from the fraction of mitochondrial oxygen
consumption rate (OCR) that is sensitive to the mitochondrial
ATP synthase inhibitor oligomycin. In the presence of lactate
and pyruvate, Bad/ hepatocytes showed a significantly higher
induction of mitochondrial ATP production (Figure 3A and Table
S1), which was restored to wild-type values after genetic intro-
duction of the BAD S155D variant, but not the BAD AAA mutant
(Figure 3A and Table S1).
Gluconeogenesis and mitochondrial FAO are interdepen-
dent. For example, fatty acids augment flux through pyruvatec.
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Figure 4. Hepatic Function of BAD Is GK
Dependent
(A) Mitochondrial OCR in GK-deficient hepato-
cytes treated with lactate and pyruvate or palmi-
tate (n = 8–10).
(B and C) Shown is mitochondrial OCR (B) and
glucose production (C) in GK-deficient hepato-
cytes transduced with the indicated adenoviruses
(n = 9). Error bars show ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001; n.s., nonsignificant. See also
Table S1.
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Regulation of Fasting Response by Hepatic BADcarboxylase, leading to significant stimulation of OCR and gluco-
neogenesis in the presence of lactate and pyruvate (Gustafson
et al., 2001; Pryor et al., 1987). Importantly, inhibition of carnitine
palmitoyl transferase (CPT1), which is required for mitochondrial
import of long-chain fatty acids, or interference with mitochon-
drial electron transport chain activity reverses these effects
(Pryor et al., 1987), indicating the importance of mitochondria
in energetic and substrate coupling between FAO and gluconeo-
genesis. This prompted examination as to whether increased
gluconeogenesis in the absence of BAD is linked to elevated
FAO. Indeed, mitochondrial OCR in response to palmitate was
significantly higher in primary Bad/ hepatocytes compared
with controls (Figure 3B and Table S1). Similar results were
also obtained in Bad knockdown hepatocytes (data not shown).
As predicted, the rise in OCR normally seen upon treatment with
lactate and pyruvate was inhibited by the mitochondrial FAO
inhibitor etomoxir (Etx) in both Bad+/+ and Bad/ hepatocytes
(Figure 3C). However, the etomoxir-inhibitable portion of this
respiratory rate was significantly larger in Bad/ than in control
hepatocytes (Figure 3C and Table S1), which is in agreement
with higher FAO in Bad/ hepatocytes (Figure 3B). This is also
consistent with a lower respiratory quotient (RQ) in Bad/
mice (Figure 3D), which reflects preferential utilization of fatty
acids as energy source. Overall, these results suggest that loss
of BAD is associated with an altered program of mitochondrial
substrate and energy metabolism that matches excess gluco-
neogenesis. Notably, these alterations do not appear to be
linked to changes in mitochondrial mass in the absence of
BAD (Figures 3E and 3F).
The functional increase in FAO in the absence of BAD
warranted examination of hepatic genes involved in fatty acid
metabolism. Comparison ofmicroarray expression profiles using
gene set enrichment analysis (GSEA) identified themitochondrial
b-oxidation pathway as the top gene set enriched in fasted
Bad/ liver compared toBad+/+ controls (Figure S3A). Quantita-
tive real-time PCR provided independent evidence for
augmented mRNA abundance of the FAO genes in Bad/ liver
(Figure S3B). Conversely, transcription of the lipogenic gene
acetyl coenzymeA (acetyl-CoA) carboxylase (Acc) wasmarkedly
downregulated in Bad/ liver (Figure S3B). Examination of key
transcriptional regulators of FAO also indicated significant in-
duction of PparamRNA in Bad/ liver (Figure S3B). Importantly,
these transcriptional changes were also observed following
acute hepatic knockdown of Bad (Figure S3C) and were furtherCell Metabolism 19, 272–284phenocopied by acute hepatic knock-
down of Gk (Figure S3D) or liver-specific
deletion of Gk (Gklox/lox versus Gklox/lox;Alb-cre; Figure S3E). These observations suggest a potential
link between BAD- and GK-dependent metabolic signaling and
hepatic gene expression.
Hepatic Function of BAD Is Mediated by GK
The differential effect of BAD S155D and AAA variants in genetic
reconstitution assays suggests that BAD’s influence on glycol-
ysis and gluconeogenesis is coordinated with its ability to
activate GK. In addition, the common phenotype of exaggerated
gluconeogenesis and FAO when either BAD or GK are acutely
depleted in the liver suggests that the functional interaction of
these two proteins is relevant for hepatic substrate metabolism.
This predicts that loss of GK would phenocopy loss of BAD in
mitochondrial energy metabolism and handling of gluconeo-
genic substrates and that BAD’s effect on hepatic substrate
utilization would be abrogated in the genetic background of Gk
deficiency. We next tested each of these predictions. Primary
Gk/ hepatocytes display marked stimulation of mitochondrial
OCR when cultured with lactate and pyruvate or palmitate
(Gklox/lox versus Gklox/lox; Alb-cre; Figures 4A and 4B; Table S1)
analogous to Bad/ hepatocytes. Gluconeogenesis was also
significantly higher in Gk null hepatocytes (Figure 4C). However,
expression of BAD S155D in Gk/ hepatocytes was ineffective
in curtailing excess mitochondrial OCR and glucose production
in the presence of lactate and pyruvate (Figures 4B and 4C).
This contrasts with the capacity of BAD S155D to correct these
parameters in Bad/ hepatocytes (Figures 2D and 3A). These
data provide genetic and mechanistic evidence consistent with
GK as a downstream mediator of BAD’s effect on hepatic sub-
strate and energy metabolism.
Hepatic Insulin Resistance in Bad–/– mice
Insulin is a critical regulator of hepatic glucose metabolism
through transcriptional and posttranslational mechanisms as
well as modulation of substrate supply (Lin and Accili, 2011;
Saltiel and Kahn, 2001). It stimulates transcription of several
glycolytic genes, including Gk, and represses that of gluconeo-
genic genes Pck1, Fbp1, and G6p. In addition, insulin stimulates
BAD phosphorylation in the liver (Figure 5A). Given the effect of
BAD phosphorylation on GK activity and hepatic substrate utili-
zation, these observations predict that BAD’s hepatic function
may be subject to insulin regulation. To test the physiologic
relevance of BAD in the context of insulin action, we performed
euglycemic-hyperinsulinemic clamp analysis. While glucose, February 4, 2014 ª2014 Elsevier Inc. 277
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Figure 5. Hepatic Insulin Resistance in the Absence of BAD
(A) Modulation of hepatic BAD phosphorylation by insulin in vivo. Immunoblot analysis and quantification of relative BAD phosphorylation on S155, S136, and
S112 in liver samples derived from C57BL/6J mice fasted overnight and injected with saline or insulin.
(B–G) Euglycemic-hyperinsulinemic clamp analysis in Bad/ and Bad+/+ mice (n = 7–9), showing plasma glucose (B), glucose infusion rate (GIR) (C), hepatic
glucose production (HGP) (D), relative mRNA abundance of hepatic gluconeogenic genes (E), hepatic glycogen synthesis rates (F), and peripheral insulin
sensitivity (G). Error bars show ± SEM. *p < 0.05; **p < 0.01; Bad/ versus Bad+/+ mice. See also Figure S4.
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the analysis (Figure 5B), Bad/ mice displayed a small, but
statistically significant, reduction in glucose infusion rates (GIR)
(51.5 ± 2.5 versus 43.4 ± 2.6 mg/kg/min, p < 0.05, Bad+/+ versus
Bad/; Figure 5C), consistent with whole-body insulin resis-
tance. As reduced GIR can derive from impaired suppression
of HGP by insulin and/or its diminished capacity to enhance
glucose uptake in peripheral tissues, hepatic and peripheral
insulin sensitivities were measured separately. Suppression of
HGP by insulin in Bad/ mice was markedly impaired, consis-
tent with hepatic insulin resistance (94.7% ± 14.7% versus
32.1% ± 14.0%, p < 0.008, Bad+/+ versus Bad/; Figure 5D).
This was further consistent with diminished capacity of insulin
to fully inhibit the transcription of Pck1, Fbp1, and the catalytic
subunit of G6p (G6pc) in Bad/ liver (Figure 5E).
To determine if hepatic insulin resistance in BAD-deficient
mice extends to abnormalities in glucose storage, the net
hepatic glycogen synthesis rates were also measured and found
to be comparable in Bad+/+ and Bad/ mice (Figure 5F). These
rates reflect the net balance of direct and indirect pathways of
glycogen synthesis (Agius, 2008). While diminished hepatic
glucose utilization inBad/mice (Figure 1A) would predict lower
glycogen synthesis via the direct pathway, increased gluconeo-
genesis in these animals may lead to a larger contribution from
the indirect pathway. It is possible that a relative increase in
the indirect pathway of glycogen synthesis may have offset
any differences in the direct pathway, rendering total glycogen
synthesis in Bad/ mice comparable to that of controls.
Notably, a prominent contribution of the gluconeogenic pathway
to hepatic glycogen synthesis in glucokinase-deficient (MODY2)
subjects has been reported (Velho et al., 1996).
Insulin resistance in Bad/ mice is restricted to liver, as
insulin-mediated glucose uptake in skeletal muscle and white
adipose tissues was not altered (Figures S4A and S4B).
Whole-body glucose uptake, glycolysis, and glycogen synthesis
did not reveal any differences in the two genotypes (Figure 5G).
Other metabolic parameters, such as fat and lean mass, energy
expenditure, and activity, as well as fasted serum levels of
glucagon, FFA, and triglycerides, were comparable in both
genotypes (Figures S4C–S4H). Overall, these results indicate
that peripheral insulin sensitivity is preserved in Bad/ mice
and that diminished GIR in this genetic model can be chiefly
attributed to impaired suppression of HGP.
Hepatic Insulin Signaling in the Absence of BAD
Impaired hepatic insulin action in Bad/mice warranted exam-
ination of insulin signaling. Insulin stimulation of phosphatidylino-
sitol 3-kinase (PI3K) activity was significantly diminished in
Bad/ liver, but not in Bad/ gastrocnemius muscle (Figures
6A and S5A). Lower hepatic PI3K activity in Bad/ was consis-
tent with reduced stimulation of AKT phosphorylation by insulin
but could not be explained by changes in insulin receptor (IR)
phosphorylation (Figure 6B). Importantly, insulin stimulation of
AKT phosphorylation was not altered in muscle (Figure S5B),
which is in agreement with selective loss of insulin action in liver,
but not in muscle (Figures 5D and S4A). Reduced AKT phosphor-
ylation in response to insulin was further evident in primary
Bad/ hepatocytes treated with insulin (Figure S5C), indicating
a cell-autonomous effect of BAD deficiency on insulin signaling.Cell MMoreover, attenuated insulin signaling in Bad/mice was reca-
pitulated in mice treated with Bad shRNA (Figure 6C). Reduced
PI3K-AKT signaling without alterations in insulin receptor phos-
phorylation predicts inhibition at the level of insulin receptor sub-
strate 1 (IRS-1) through negative feedback loops (Copps and
White, 2012). Examination of several IRS-1 inhibitory kinases re-
vealed comparable hepatic c-Jun amino-terminal kinase (JNK)
and extracellular signal-regulated kinase (ERK) phosphorylation
but diminished glycogen synthase kinase-3 (GSK-3) phosphory-
lation in Bad shRNA liver (Figure 6C and data not shown).
Because phosphorylation inactivates GSK-3, these results indi-
cate increased hepatic GSK-3 activity in BAD-depleted liver.
However, GSK-3 phosphorylation is itself regulated by insulin,
similar to several other IRS-1 inhibitory kinases (Copps and
White, 2012), and whether GSK-3 activity is the cause or conse-
quence of reduced insulin signaling in these mice remains to be
determined. Importantly, an analogous decline in hepatic insulin
signaling was also observed in mice treated withGk shRNA (Fig-
ure 6D). This is consistent with published reports that loss of GK
or inhibition of its activity is associated with blunted suppression
of HGP and hepatic insulin resistance (Barzilai et al., 1996;
Cle´ment et al., 1996; Rossetti et al., 1997). In aggregate, our find-
ings indicate that, similar to hepatic depletion or inhibition of GK,
loss of BAD and the attendant diminution of GK activity are
associated with reduced hepatic insulin sensitivity and insulin
signaling.
Hepatic GK and BAD are both regulated by insulin. Gk is a
transcriptional target of sterol regulatory element-binding pro-
tein 1c (SREBP1c) downstream of the PI3K-AKT axis, and BAD
phosphorylation, which stimulates GK activity (Figure S2B)
(Szlyk et al., 2014), is induced by insulin (Figure 5A). It is therefore
possible that BADmay serve as an additional downstreammedi-
ator of insulin’s effect on GK, whereby insulin stimulates GK
activity beyond induction of Gk transcription. Given insulin regu-
lation of BAD and GK and reduced insulin signaling in Bad/
mice, two potential scenarios may explain the diminished insulin
suppression of HGP in thesemice: diminished insulin stimulation
ofGk expression or diminished capacity of insulin to enhanceGK
activity through BAD phosphorylation. To determine changes in
Gk expression in this setting, we examined hepatic Srebp1c and
Gk mRNA levels in Bad+/+ and Bad/ mice subjected to
euglycemic-hyperinsulinemic clamp. Relative Srebp1c mRNA
abundance was lower in Bad/ liver (Figure S5D), which is
consistent with reduced insulin stimulation of PI3K-AKT
signaling in these mice. Surprisingly, however, Gk mRNA levels
were not diminished in these samples (Figure S5E), suggesting
potential SREBP1c-independent compensatory mechanisms
that maintain Gk mRNA levels despite reduced insulin signaling
in Bad/ liver. Notably, several other transcription factors can
directly activate the Gk promoter in the absence of SREBP1c
(Bechmann et al., 2012; Kim et al., 2009; Oosterveer et al.,
2012). Moreover, Gk mRNA levels can be regulated by 6-phos-
phofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2) inde-
pendent of insulin and SREBP1c (Payne et al., 2005; Wu et al.,
2004). Therefore, it is possible that one or more of these
mechanisms may stabilize Gk expression in Bad/ liver under
these conditions. In addition, the potential contribution of
residual insulin signaling in these mice cannot be ruled out.
Regardless of the mechanisms that may stabilize Gk mRNAetabolism 19, 272–284, February 4, 2014 ª2014 Elsevier Inc. 279
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Figure 7. Metabolic Effects of BAD in ob/ob
and HFD-Treated Mice
(A–D) Shown are fasting glucose levels (A), liver
Pck1 mRNA abundance (B), and pyruvate (C) and
glucose (D) tolerance tests following hepatic
reconstitution of ob/ob mice with the indicated
adenoviruses (n = 10–14). Asterisks in (C) and (D)
compare ob/ob mice treated with BAD S155D
versus GFP adenoviruses.
(E) GTT in C57BL/6J mice subjected to high-fat
diet for 10 weeks prior to hepatic reconstitution
with the indicated adenoviruses (n = 9). Asterisks in
(E) compare HFD mice treated with BAD S155D
versus GFP adenoviruses. Error bars show ± SEM.
*p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S6.
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Regulation of Fasting Response by Hepatic BADlevels in Bad/mice, our results indicate that diminished insulin
suppression of HGP in these animals cannot be explained by
diminished Gk transcription. Considering insulin induction of
BAD phosphorylation on S155 and the direct stimulatory effect
of the phospho-BAD BH3 domain on GK activity (Szlyk et al.,
2014), our data are most consistent with the proposal that defec-Figure 6. Altered Insulin Signaling upon Hepatic Manipulation of BAD and GK
(A) IRS-1-associated PI3K activity in liver of Bad+/+ and Bad/ mice injected with saline or insulin after an o
(B) Phosphorylation of the insulin receptor (IR) and AKT in liver ofBad+/+ andBad/mice treated as in (A). Bar
AKT phosphorylation (n = 4).
(C and D) Insulin signaling in liver samples isolated from C57BL/6J mice following hepatic knockdown of Bad
induction of IR, AKT, and GSK-3 phosphorylation (n = 4). Error bars show ± SEM. *p < 0.05; **p < 0.01; ***p
Cell Metabolism 19, 272–284tive GK activity in Bad/ liver, despite
stabilized Gk mRNA levels, may curtail
the full effect of insulin on proper modula-
tion of HGP.
Metabolic Benefits of BAD in
Models of Diabetes and Insulin
Resistance
The capacity of BAD S155D to counter-
balance exaggerated gluconeogenesis
in Bad/ liver warranted examination of
its effect in models of diabetes and insulin
resistance such as ob/ob mice. Hepatic
BAD protein levels were comparable in
ob/ob and control ob/+ mice despite
elevated Bad mRNA levels in ob/ob ani-
mals, indicating that increased transcrip-
tion of the Bad gene does not result in
higher protein levels in this context (Fig-
ures S6A and S6B). Remarkably, how-
ever, BAD phosphorylation on S155 and
S136 was significantly diminished in ob/
ob liver (Figure S6C). These observations
further motivated examination of whether
expression of a BAD S155D can alter
hepatic metabolism in these animals.
Hepatic delivery of BAD S155D, but
not BAD AAA, significantly ameliorated
fasting hyperglycemia in ob/ob mice(Figure 7A), which was accompanied by diminished fasting
Pck1 mRNA abundance (Figure 7B). Importantly, glucose levels
during PTT were markedly downregulated in ob/ob mice recon-
stituted with BAD S155D adenoviruses so that they were com-
parable to ob/+ controls treated with GFP viruses (Figure 7C).
BAD S155D expression further resulted in systemic metabolicvernight fast (n = 10 per genotype).
graphs quantitate relative insulin induction of IR and
(C) andGk (D). Bar graphs quantitate relative insulin
< 0.001. See also Figure S5.
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(Figure 7D).
We next set out to determine whether the differential effects of
BAD S155D and BAD AAA in ob/ob liver parallel their GK-
activating capacity. Previous studies have reported an age-
dependent progressive decline in hepatic Gk mRNA and GK
activity in leptin-resistant rodent models (Torres et al., 2009).
Importantly, increased GK activity through chemical or genetic
approaches improved glucose homeostasis in these models
(Grimsby et al., 2003; Torres et al., 2009). Hepatic expression
of BAD S155D or BAD AAA variants did not alterGkmRNA levels
in ob/ob mice (Figure S6D) but had a distinct effect on GK
activity. Specifically, BAD S155D increased hepatic GK activity,
whereas the BAD AAA variant was ineffective (Figure S6E). Thus,
the differential effect of BAD phospho-mutants in hepatic
reconstitution of ob/ob mice cosegregates with their effect on
GK activity.
The ob/ob genetic model is a severe model of diabetes with a
complex myriad of chronic pathophysiologic perturbations. We
also tested the metabolic consequence of BAD in the high-fat
diet (HFD) model. Acute hepatic delivery of BAD S155D to
wild-type mice after 10 weeks of high-fat feeding effectively
improved fasting hyperglycemia and glucose tolerance, while
the BAD AAA variant was inert in this setting (Figure 7E). The
glucose tolerance test (GTT) profiles of HFD mice treated with
BAD S155D were comparable to normal chow (control)-fed
mice treated with GFP viruses (Figure 7E).
DISCUSSION
Our combined use of multiple genetic tools, including the Bad
null and phosphorylation knockinmice, liver-specificBad knock-
down, as well as informative BAD mutants enabled biochemical
and systemic evaluation of BAD’s significance in hepatic sub-
strate metabolism. These studies show that hepatic loss of
BAD or interference with its phosphorylation is linked to reduced
glycolysis, enhanced FAO, and unrestrained gluconeogenesis.
Moreover, BAD deficiency is associated with impaired insulin-
mediated suppression of HGP and attenuated insulin signaling.
Our collective observations suggest that exaggerated gluconeo-
genesis in the absence of BAD can be mapped to a combination
of altered substrate and energy metabolism, as well as loss of
hepatic insulin sensitivity.
BAD’s capacity to modulate hepatic glucose utilization and
production is regulated by its phosphorylation, which is in turn
sensitive to the fed and fasted nutritional states and insulin.
When phosphorylated, BAD activates GK, promoting glycolysis
and inhibiting FAO. Upon BAD dephosphorylation, glycolysis is
diminished, FAO is disinhibited, and pyruvate is preferentially
partitioned to gluconeogenesis. These observations are consis-
tent with the possibility that BAD phosphorylation may helpmito-
chondria distinguish the glycolytic versus gluconeogenic source
of pyruvate and its metabolic fate. The idea that GK is an impor-
tant mechanistic component of BAD modulation of hepatic
metabolism is supported by two lines of investigation. First, the
selective capacity of BAD BH3 variants to modulate hepatic
metabolism in both primary hepatocytes and whole-animal
liver reconstitution assays cosegregates with their differential
GK-activating property. Second, BAD’s ability to coordinately282 Cell Metabolism 19, 272–284, February 4, 2014 ª2014 Elsevier Inregulate hepatic energy metabolism and gluconeogenesis is
abolished in the absence of GK, providing evidence in favor of
an epistatic relationship between these partner proteins in which
GK is a downstream mediator of BAD’s metabolic effects.
The notion that the BAD-GK axis is relevant for proper regula-
tion of glycolysis and gluconeogenesis is consistent with several
metabolic alterations that are phenocopied when each protein is
depleted in the liver, including exaggerated gluconeogenesis
and impaired glucose tolerance. Hepatic GK is subject to several
regulatory mechanisms, including distinct binding interactions
and subcellular localization (Matschinsky, 2009). BAD deficiency
does not lead to reduced hepatic GK expression at mRNA or
protein levels but is associated with diminished GK activity.
Given the multiple mechanisms that converge on hepatic GK
regulation, loss of BAD is not expected to recapitulate the full
phenotypic spectrum of GK loss of function in the liver. Within
this context, the finding that several metabolic alterations are
shared between mice with hepatic knockdown of Bad and
animals with hepatic knockdown of Gk is remarkable.
Changes in hepatic metabolism following depletion of BAD or
GK also include altered expression of several glycolytic and
gluconeogenic genes and a robust transcriptional activation of
b-oxidation. This gives rise to the question of how BAD- or GK-
dependent changes in hepatic metabolism modify gene expres-
sion. Because these changes can be acutely triggered by the
knockdown of either BAD or GK, it is likely that select alterations
in glucose- or fatty acid-derived metabolites may modulate the
activity of glucose- and fatty acid-sensing transcription factors
such as carbohydrate-responsive element-binding protein
(ChREBP) and nuclear receptors (Agius, 2013; Jump et al.,
2013). Another possible scenario is alterations in chromatin-
and histone-modifying enzymes that can be modulated by
defined metabolites or cellular metabolic state (Kaelin and
McKnight, 2013).
Our findings indicate that deregulated gluconeogenesis in the
absence of BAD also extends to diminished insulin suppression
of HGP. BAD phosphorylation, which can downregulate gluco-
neogenesis through GK activation (Figures 2C, 2D, S2B, and
4C), is normally induced by insulin. This observation, together
with the finding that insulin suppression of HGP is diminished
in Bad/mice, suggests that BAD may serve as a downstream
effector of insulin in modulation of hepatic glucose production.
Moreover, hepatic insulin resistance in the absence of BAD is
accompanied by changes in insulin signaling. Hepatic nutrient
and energy sensing pathways and insulin signaling are tightly
integrated (Newgard, 2012; Samuel and Shulman, 2012), and
the shared phenotype of reduced insulin signaling upon acute
hepatic depletion of BAD or GK predicts a potential interplay
between reduced glucose utilization and/or increased FAO and
the components of the insulin signaling axis. Notably, precedent
for a link between glucose metabolism, ROS, and NADH and the
regulation of PI3K-AKT-GSK-3 signaling exists in other tissues
(Pelicano et al., 2006; Yeshao et al., 2005). The precisemolecular
link between BAD- and GK-dependent changes in substrate
metabolism and alterations in insulin signaling awaits additional
studies.
The observation that hepatic delivery of BAD S155D reinstates
proper regulation of gluconeogenesis and allays fasting hyper-
glycemia in the ob/ob and HFD-treatedmice provides a powerfulc.
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gulation. We have shown that the BAD S155D variant and hydro-
carbon-stapled BAD BH3 helices that bear the phosphomimic
S155Dmodification (BAD SAHB compounds) can directly trigger
GK activity and stimulate insulin secretion in primary islets
(Danial et al., 2008; Szlyk et al., 2014). The studies presented
here suggest that in addition to boosting b cell function, BAD
BH3 phosphomimic strategies may improve hepatic meta-
bolism. This is consistent with published reports that GK activa-
tion imparts benefits to both b cells and hepatocytes. Hepatic
GK activation using genetic approaches or pharmacologic tools
such as small molecule allosteric GK activators (GKAs) leads to
increased glucose utilization, decreased glucose production,
amelioration of hyperglycemia, and resistance to HFD (Ferre
et al., 1996; Grimsby et al., 2003; Torres et al., 2009). However,
these benefits have to be carefully leveraged against potential
risk of hypoglycemia and hyperlipidemia associated with chronic
GK activation above physiologic levels (Meininger et al., 2011).
With advances in the development of different classes of GKAs
that may elicit distinct mechanisms of action and the possibility
of combination therapy with other antidiabetic agents, the bene-
fits of GK activation may ultimately outweigh these drawbacks
(Matschinsky, 2009). Within this context, it is important to note
that the mechanism by which the phospho-BAD BH3 helix acti-
vates GK is distinct from allosteric GKAs (Szlyk et al., 2014), sug-
gesting that phospho-BADBH3mimetic compoundsmay define
a separate class of GKAs. The findings reported here highlight
the potential therapeutic utility of phospho-BAD BH3 mimetic
strategies in diabetes and metabolic syndrome.
EXPERIMENTAL PROCEDURES
Mice
Bad/ and S155A knockin mice have been previously described (Danial et al.,
2008). These mice have been bred into the C57BL/6J genetic background for
at least 14 generations and validated by genome scanning to be 99.9% con-
genic with C57BL/6J. Conditional Gk mice (Gklox/lox) were a generous gift of
Dr. Mark Magnuson (Vanderbilt University) (Postic et al., 1999). C57BL/6J
alb-cre mice and ob/ob mice were purchased from Jackson Laboratory and
Taconic, respectively. Mice received a standard chow or high-fat diet (55%
fat energy, TD93075, Harlan Laboratories) and were housed in a barrier facility
with 12 hr light and dark cycles. Unless otherwise indicated, male mice at
10–12 weeks of age were used. All animal procedures were approved by the
Institutional Animal Care and Use Committee of Dana-Farber Cancer Institute
and Yale University School of Medicine.
Metabolic Studies
PTT, GTT, basal metabolic characterization, and euglycemic-hyperinsulinemic
clampswere performed as previously described (Choi et al., 2007; Danial et al.,
2008; Lin et al., 2004). Adenoviral transduction was carried out as described in
the Supplemental Experimental Procedures.
Mitochondrial Respirometry
OCRwas measured in intact hepatocytes in real time using the XF24 Extracel-
lular Flux Analyzer and the XF24 v1.5.0.69 software (Seahorse Bioscience).
Cells were seeded on collagen-coated XF24 V7 plates at 4 3 104 cells/well,
allowed to attach for at least 2 hr, rinsed once, and kept in 600 ml of sodium
bicarbonate-free M199medium supplemented with 1%BSA, 1 mMdexameth-
asone, and 12 mM forskolin. After baseline measurements, additions were
delivered in the following order through the instrument’s individual injection
ports: substrates (lactate and pyruvate or palmitate), ADP, and oligomycin.
L-lactate (Sigma) and sodium pyruvate (Cellgro, Mediatech) were injected at
10 and 1 mM, respectively. Sodium palmitate (Sigma) was injected atCell M200 mM together with 10 mM L-malate (Sigma). When palmitate was tested,
0.5 mM carnitine (Sigma) was included in the incubation and equilibration
medium. Where indicated, etomoxir (Sigma) was included in incubation and
equilibration medium at 50 mM final concentration. After addition of the
substrates, 5 mM ADP (Sigma) was injected to drive maximum respiration.
Lastly, 1 mM oligomycin (Calbiochem) was injected to derive the portion of
OCR used for ATP synthesis. OCR values in Figures 3 and 4 represent the
difference between the maximal rate in the presence of ADP and the rate after
addition of oligomycin, thus indicating ATP production by mitochondrial
oxidative phosphorylation. Additional experimental details and a summary
table of OCR values in the presence and absence of ADP for all substrates
and genotypes tested are provided in Table S1 and the Supplemental
Experimental Procedures.
Statistical Analysis
Data are presented as mean ± SEM of the indicated number of independent
experiments or mice per genotype. Statistical significance among the groups
was tested with unpaired or paired Student’s t test and ANOVA when appro-
priate. Differences were considered significant at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2013.12.001.
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